EDIT Editas Medicine, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
13:05
Aug 17
Aug 17
Shares options positioning net conviction data.
Shares options positioning data showing net conviction based on fund holdings, no directional view.
MED
08:31
Feb 01
Feb 01
Beaten-down CRISPR name with asymmetric repricing potential
The author argues Editas Medicine is a real CRISPR company with actual IP and ongoing eye and liver programs whose stock has been destroyed by dilution, biotech winter, and bad sentiment, leaving expectations near zero. Because the market cap is low, any positive development such as data, a partnership, or an asset sale could cause a hard repricing. The author frames this as high risk/high reward, noting it could bleed for a long time before suddenly moving, and claims a 10x is possible.
HIGH
About EDIT Investor Commentary
Across the available history and selected sources, Buzzberg tracks EDIT (Editas Medicine, Inc.) across 2 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: seedy19tron, u/Adrian_TTV.